Philadelphia, Pennsylvania, December 8, 2025
Medicus Pharma Ltd. has appointed Carolyn Bonner as Chief Financial Officer while maintaining her role as President, following the resignation of former CFO James Quinlan. This strategic move aims to align financial strategies and corporate objectives during a crucial transition for the company. Bonner brings nearly 20 years of experience in healthcare, further strengthening Medicus’s pipeline and operational efficiency amid advancements in clinical studies and acquisitions.
Medicus Pharma Appoints New CFO in Strategic Move
Leadership transition aims to enhance financial strategy and corporate objectives.
Philadelphia, Pennsylvania – Medicus Pharma Ltd. has made a significant leadership change by appointing Carolyn Bonner as its Chief Financial Officer (CFO), while she continues her role as President. This decision follows the formal resignation of former CFO James Quinlan due to health reasons. Bonner has been serving as Acting CFO since September 2025, demonstrating her capability and leadership during this transitional phase.
Dr. Raza Bokhari, the Executive Chairman and CEO of Medicus, expressed confidence in Bonner’s extensive experience and strategic vision to guide the company forward. Her dual role not only ensures alignment with corporate objectives but also fosters continuity during a pivotal time in the company’s evolution.
Background on Carolyn Bonner
Carolyn Bonner brings nearly 20 years of expertise in the healthcare and life sciences sectors to her position. Before joining Medicus, she served as President and CEO of PCL, Inc., a specialty laboratory with operations in the United States and the United Arab Emirates. Her prior experience also includes leadership roles in business and corporate development across various prestigious organizations.
Expanded Responsibilities
In her new role as both President and CFO, Bonner will oversee crucial areas including financial reporting, capital markets strategy, budgeting, and treasury operations. Furthermore, she will continue to lead strategic planning initiatives across the company’s clinical and corporate development activities. This integrated leadership approach is designed to propel Medicus toward achieving its ambitious goals while enhancing operational efficiency.
Advancements in Medicus Pharma’s Pipeline
Medicus Pharma is currently focused on advancing its pipeline, specifically with the ongoing Phase 2 clinical studies of its innovative SkinJect technology. This solution utilizes dissolvable doxorubicin-containing microneedle arrays aimed at non-invasively addressing basal cell carcinoma of the skin. The company has recently expanded its trials to the United Kingdom, having gained necessary regulatory approvals, which reflects a proactive approach to global market opportunities.
Strategic Acquisition and Product Development
Further enhancing its portfolio, Medicus completed the acquisition of UK-based Antev Limited in August 2025. This acquisition has enabled the inclusion of Teverelix, a GnRH antagonist intended for prostate cancer patients with cardiovascular risks, into Medicus’s developmental pipeline. Such strategic moves underscore Medicus’s commitment to innovation in therapeutics and addressing critical health challenges.
The Role of Leadership in Growth
The recent leadership transitions at Medicus highlight the importance of resilient leadership in navigating the complexities of the biotech landscape. James Quinlan, a co-founder of the company, played a significant role in its earlier successes, including the reverse takeover of Skinject, Inc. and its successful public listing on Nasdaq in November 2024. The transition marks a continuation of a legacy rooted in pioneering medical solutions.
Conclusion
Medicus Pharma Ltd.’s strategic leadership changes and focus on cutting-edge therapeutic innovations exemplify the resilience and entrepreneurial spirit characteristic of the Philadelphia business community. As the company navigates this new phase under Bonner’s stewardship, there are ample opportunities for continued growth and positive impacts on healthcare outcomes. Supporting local firms like Medicus is crucial for fostering an environment where innovation thrives. Stay informed and engaged in Philadelphia’s evolving economic landscape.
Frequently Asked Questions (FAQ)
Who is Carolyn Bonner?
Carolyn Bonner is the President and Chief Financial Officer of Medicus Pharma Ltd. She has nearly 20 years of experience in the healthcare and life sciences sectors, including leadership roles at PCL, Inc., Rosetta Genomics Ltd., and Inform Diagnostics, Inc.
What is Medicus Pharma Ltd.?
Medicus Pharma Ltd. is a precision-guided biotech and life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets.
What is the SkinJect technology?
SkinJect is a technology developed by Medicus Pharma that uses dissolvable doxorubicin-containing microneedle arrays to non-invasively treat basal cell carcinoma of the skin.
What is Teverelix?
Teverelix is a GnRH antagonist being developed by Antev Limited, which was acquired by Medicus Pharma in August 2025. It is intended for prostate cancer patients with cardiovascular risks.
Who is James Quinlan?
James Quinlan is a co-founder of Medicus Pharma Ltd. He played a key role in the company’s reverse takeover of Skinject, Inc., as well as its initial public offering and listing on Nasdaq in November 2024.
What is the Medicines and Healthcare products Regulatory Agency?
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK government agency responsible for regulating medicines, medical devices, and blood components for transfusion in the United Kingdom.
What is a GnRH antagonist?
A GnRH antagonist is a type of medication that inhibits the release of gonadotropin-releasing hormone (GnRH), which plays a role in regulating reproductive hormones. In the context of prostate cancer, GnRH antagonists are used to reduce testosterone levels, which can fuel cancer growth.
What is basal cell carcinoma?
Basal cell carcinoma is a type of skin cancer that begins in the basal cells, which are located in the lower part of the epidermis. It is the most common type of skin cancer and typically grows slowly, often appearing as a small, shiny bump or nodule on the skin.
What is a reverse takeover?
A reverse takeover is a type of merger where a private company acquires a publicly listed company, allowing the private company to become publicly traded without going through the traditional initial public offering process.
What is an initial public offering (IPO)?
An initial public offering (IPO) is the process by which a private company offers its shares to the public for the first time, becoming a publicly traded company.
What is Nasdaq?
Nasdaq is an American stock exchange, known for its high-tech and internet-based companies. It is the second-largest stock exchange in the world by market capitalization.
What is the role of a Chief Financial Officer (CFO)?
A Chief Financial Officer (CFO) is a senior executive responsible for managing the financial actions of a company. This includes overseeing financial reporting, capital markets strategy, budgeting, and treasury operations.
What is the role of a President in a company?
The President of a company is typically responsible for overseeing the day-to-day operations and implementing the company’s strategic plans. In some organizations, the President may also hold the title of Chief Executive Officer (CEO).
What is the role of an Executive Chairman?
An Executive Chairman is a senior leadership position in a company, often responsible for overseeing the board of directors and providing strategic guidance to the CEO and management team.
| Key Features | Description |
|---|---|
| New CFO | Carolyn Bonner appointed as Chief Financial Officer while retaining her role as President. |
| Experience | Bonner brings nearly 20 years of experience in healthcare and life sciences. |
| SkinJect Technology | Technology for non-invasive treatment of basal cell carcinoma undergoing Phase 2 clinical studies. |
| Regulatory Approvals | Trials expanded to the UK after receiving approvals from the Medicines and Healthcare products Regulatory Agency. |
| Acquisition | Medicus acquired Antev Limited, adding Teverelix to the product pipeline. |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE PHILADELPHIA WRITER
The PHILADELPHIA STAFF WRITER represents the experienced team at HEREPhiladelphia.com, your go-to source for actionable local news and information in Philadelphia, Philadelphia County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Mummers Parade, Philadelphia Flower Show, and Thanksgiving Day Parade. Our coverage extends to key organizations like the Greater Philadelphia Chamber of Commerce and United Way of Greater Philadelphia, plus leading businesses in telecommunications, food services, and healthcare that power the local economy such as Comcast, Aramark, and Children's Hospital of Philadelphia. As part of the broader HERE network, we provide comprehensive, credible insights into Pennsylvania's dynamic landscape.
